Hibifolin

• CAS: 55366-56-8
• Catalog Number: ACM55366568
• Category: Inhibitors
• Molecular Weight: 494.36
• Molecular Formula: C21H18O14
• Description: Hibifolin is a flavonol glycoside that prevents beta-amyloid-induced neurotoxicity in vitro. Hibifolin prevents beta-amyloid-induced neurotoxicity in cultured cortical neurons. Hibifolin is a potential inhibitor of adenosine deaminase.
• Synonyms: Hibifolin; Gossypetin 8-O-beta-D-glucuronide
• IUPAC Name: beta-D-Glucopyranosiduronic acid, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-1-benzopyran-8-yl
• Canonical SMILES: O[C@H]([C@H]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1OC2=C3C(C(C(O)=C(C4=CC=C(O)C(O)=C4)O3)=O)=C(O)C=C2O
• InChI: InChI=1S/C21H18O14/c22-6-2-1-5(3-7(6)23)16-13(28)11(26)10-8(24)4-9(25)17(18(10)33-16)34-21-15(30)12(27)14(29)19(35-21)20(31)32/h1-4,12,14-15,19,21-25,27-30H,(H,31,32)/t12-,14-,15+,19-,21+/m0/s1
• InChI Key: KHVMAMXQPVHXTJ-ORYXKJSJSA-N
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Shelf Life: >3 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Biological Target: Hibifolin, a flavonol glycoside, is a potential inhibitor of adenosine deaminase (ADA), with a Ki of 49.92 μM.
• Drug Formulation: This drug may be formulated in DMSO
• Elemental Analysis: C, 51.02; H, 3.67; O, 45.31
• Exact Mass: 494.0697
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: This study first identified SrtA inhibitors from the natural compound using detection of the fluorescence intensity of the fluorescent substrate peptide Abz-LPATG-Dap (Dnp)-NH2 (Fig. 1A, left), which identified that the activity of hibifolin remarkably inhibited the activity of SrtA with an IC50 of 31.20 μg/mL (Fig. 1C). Hibifolin was able to inhibit the activity of SrtA and neither affected bacterial growth nor had cytotoxicity. These characteristics suggested that hibifolin has potential for development as a SrtA inhibitor.; Reference: Microbiol Spectr. 2022 Aug 31;10(4):e0095022. https://pubmed.ncbi.nlm.nih.gov/35913166/
• In Vivo Activity: In survival experiments, the survival rate of the infected mice was only 10% after 72 h of infection with S. aureus (2 × 108 CFU), while the survival rate of the cefotaxime-treated group was 60%. The combination of hibifolin and cefotaxime increased survival by 20% compared to cefotaxime alone. These data revealed that hibifolin in combination with cefotaxime protected mice from USA300 infection-induced pneumonia, which was more potent than cefotaxime alone.; Reference: Microbiol Spectr. 2022 Aug 31;10(4):e0095022. https://pubmed.ncbi.nlm.nih.gov/35913166/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).